Slide 1: Investor Presentation
Investor Presentation December 2022
Slide 2: Disclaimer
Disclaimer This presentation was prepared for informational purposes only by Moolec Science Limited, (“Moolec”) and LightJump Acquisition Corporation (“LightJump”) and is intended to be provided only to accredited institutional investors who are considering an investment in Moolec. The information p
Slide 3: Planting the Future of Food
Planting the Future of Food Moolec is a science-based food ingredient company focused on the use of Molecular Farming technology. Our purpose is to upgrade taste, nutrition, and affordability of alternative protein products while building a more sustainable and equitable food system. SCIENCE IN ALTE
Slide 4: Business Model
Business Model Moolec's innovation starts at the beginning of the food value chain. Plant-based B2B Food Producers & Animal Protein Model Contracted CPG Modified Ingredients Companies Retail / Food Consumers Seeds Growers & Downstream Services Moolec’s IP Ingredient Companies Partnership or Licensing
Slide 5: Moolec's Operations
Moolec's Operations We operate through hubs in established locations where cutting-edge R&D and science services are provided, and optimal natural conditions for crop development are present. Food Science Hub Crop Science & Cultivation Washington WISCONSIN CROP INNOVATION CENTER State University Mol
Slide 6: World Class Management Team
World Class Management Team Top Ph.Ds and recognized professionals that come from all over the world conform Moolec’s team in line with our global ambitions and targeted footprint. Gastón Paladini, MBA Henk Hoogenkamp, Ph.D Amit Dhingra, Ph.D José López Lecube, MBA Martín Salinas, Ph.D Catalina Jone
Slide 7: Pro-Forma Ownership
Pro-Forma Ownership 1 2 100.0% 3 The Biotech 4 Company LLC 80.0% 20.0% BG Farming 5 New Company Initial LJAQ Public Other 8 Technologies Ltd. Shareholders6 Stockholders 7 Stockholders Investors (NASDAQ:BIOX) 4.7% 37.0% 37.0% 3.8% 6.5% 7.0% 3.9% 9 Pre de-SPAC shareholders New Shareholders 6 Reflects
Slide 8: Moolec by the Numbers
Moolec by the Numbers The company is pioneering the future of alternative protein production with Molecular Farming technology. $65B 1st 20+ Total Addressable Market Team to achieve a bovine Global Patents & (2025E)1 protein with plants for food2 Patent Applications3 60x 35x 100% Less GHG Emissions
Slide 9: A spin-off from Bioceres Group
A spin-off from Bioceres Group Bioceres transferred full ownership of patents and 10+ years experience in Molecular Farming technology to form a standalone, food-science-focused company. Science for a Science applied to sustainable agriculture alternative proteins Scientific Team +Intellectual Prope
Slide 10: Moolec's Pathway to Public Listing
Moolec’s Pathway to Public Listing 10 years building our technology Technology scale-up Lab SPC Patents Industrial Spin-off From Safflower Company Expected Pilot plant Approvals Scale (UK Entity) to Soy Building Listing 2008 2014 2018 2020 2021 2022 GLA IP Incorporation Proof of Concept (Bioceres S.
Slide 11: Backers & Partners
Backers & Partners Moolec's shareholders and strategic partners bring key experience, advisory, scientific know-how, and access to facilities to strengthen the business. Science + Operations Finance Molecular Biology + Scale Up Provider of ag-tech solutions enabling Strategic Joint Venture the transi
Slide 12: Why Moolec?
Why Moolec? 01 Category creators: science-based & high-value added company pioneer of the 4th technological pillar within the alternative protein industry. 02 Massive addressable market: sizeable TAM1 and industry trends support significant growth opportunities. 03 Unmatched value proposition: advant
Slide 13: The Industry
The Industry
Slide 14: Food Crisis: Ring of Fire
Food Crisis: Ring of Fire Weakness of global food supply chain is on the spotlight due to present context. Economic1 Environmental3 Nutrition5 Pests & Diseases7 • War in Ukraine is • Rising average global • 25.9% of the global • The $100B toll of a pig amplifying global climate temperature and popul
Slide 15: Food System Overview
Food System Overview 1 Plants Animals 8 People Billions 7 Soybean: 6 most consumed Global Meat Animal welfare claimed 5 Human population meat analogue Products Market: to be the one of the 4 since 1800 with the highest $1 trillion most important factors protein content 3 for consumers 2 1 USA & Arge
Slide 16: Total Addressable Market
Total Addressable Market 1 Massive opportunity to play in a double-digit growing industry (17% CAGR). 90% $300B 72% 55% $140B 28% 45% $65B $40B 10% 2022 2025 2030 2035 Alternative Protein Traditional Meat Consumption Share (%) Alternative Meat Consumption Share (%) .16 SCIENCE IN 1 Sources: ALTERNAT
Slide 17: Alternative Proteins Industry
Alternative Proteins Industry Emerging industry where companies use different technologies and ingredients based on plants, cells, and microbes to address the main food challenges. Plant-Based 1 Fermentation 2 Cultured Meat 3 Products made from plants that are Use of intact live microorganisms to Ge
Slide 18: Taste and texture, Nutritional values, Scalability and low costs
Taste and Nutritional Scalability texture values and low costs .18 SCIENCE IN ALTERNATIVE PROTEINS
Slide 19: The solution: Moolec as a Category Creator
The solution: Moolec as a Category Creator 1 Molecular Farming has the potential to overcome the main obstacles faced by other technologies in the alternative protein landscape. Plant-based Fermentation Cultured meat Molecular Farming Taste and texture Nutritional values Scalability and low costs Pl
Slide 20: Molecular Farming Ecosystem
Molecular Farming Ecosystem 1 The industry is growing with stronger recognition of the advantages of Molecular Farming. Moolec is the only player focused on growing meat proteins in both soy and pea seeds. Nobell Foods2 Miruku3 VelozBio4 Tiamat Sciences8 Core Biogenesis9 Dairy proteins in soybeans D
Slide 21: The Technology
m Moolec Cis @ ‘fi N 4 | % ~~ Vag ! ( ~ 4 ‘ , a , Fw nee s JimeA
Slide 22: Animal Proteins in Plants
Animal Proteins in Plants Moolec introduces real animal genes in the plant's genome to give real taste and nutrition to food. Traditional Seeds Crops Feed Livestock Food ed animal proteins Plant-bas Molecular Seeds Crops Cruelty-Free Farming Food Anima eering l proteins - Genetic engin .22 SCIENCE I
Slide 23: Molecular Farming: a cost-effective way to produce alternative proteins
Molecular Farming: a cost-effective way to produce alternative proteins 1 .23 SCIENCE IN 1 Moolec's internal analysis based on publicly disclosed information for the industry and management estimates ALTERNATIVE PROTEINS
Slide 24: Moolec vs. Animal-based Production System
Moolec vs. Animal-based Production System Molecular Farming is more friendly to the environment when compared to traditional protein productive systems. 1 8X less2 3 .24 SCIENCE IN 1 https://ourworldindata.org/agricultural-land-by-global-diets ALTERNATIVE 2 https://waterfootprint.org/en/water-footpr
Slide 25: Molecular Farming in a Nutshell
Molecular Farming in a Nutshell Selection Transformation Development Production Scale-Up .01 Real DNA .03 Vector is .05 Engineered .07Seeds are (protein of inserted into plant cells grow into harvested and interest) is isolated chromosomes whole plants crushed Gene is Cells expressing Plants grow fir
Slide 26: Proof of Concept: Why Chymosin?
Proof of Concept: Why Chymosin? Chymosin is a validation molecule in biotechnology by being the first protein for food been approved by the FDA with precision fermentation Fermentation Molecular Farming 90’s 2010 Plant-Based Bovine Protein Safflower Crops Safflower Seeds Cheese ingredient Bovine Gene
Slide 27: Transferrable & scalable technology
Transferrable & scalable technology Based on our Proof of Concept we were able to extend our technology to new hosts with enhanced features. Soy proteins + Plant-Based Meat Proteins Chymosin Safflower Soy Protein content 20% 40% Scalability 120K has 50M has Yield 1 ton/ha 5 ton/ha Market 350M Chymos
Slide 28: Fermentation: Our Validation Platform
Fermentation: Our Validation Platform Precision fermentation complements Molecular Farming technology as validation stage and faster go-to-market pathway. Fast application testing Partnerships and commercial Quick regulatory footprint opportunities IP discovery Product development Technological Stra
Slide 29: Pipeline & Products
| 4a > y in Xt. ¢ A os < ha! Mey, 0% ~~. 2
Slide 30: Pipeline Status
Pipeline Status R&D OPERATIONS PLANED REGULATION SAM2 PROGRAM HOST PROJECT PHASE1 COMMERCIAL 2025 DISCOVERY PROOF OF EARLY ADVANCED PRE-LAUNCH PRODUCT LAUNCH STATUS CONCEPT DEVELOPMENT DEVELOPMENT LAUNCH Dairy ingredient and SPC2 - 2025 350M3 Nutritional oil Safflower (Chymosin & GLA) GLASO - 2025 1
Slide 31: Plant-Based Meat Ingredients by Weight
Plant-Based Meat Ingredients by Weight1 Flavouring & Appearance Binding & Texturizing Alternative meat industry still uses traditional 5% ingredients, limiting it from overcoming major 5% challenges and meeting consumer expectations. 20% Plant 50% Proteins Water Current industry 20% challenges Sunflo
Slide 32: Moolec's Substitute Process by Cost
Moolec's Substitute Process by Cost 1 PHASE 1 PHASE 2 PHASE 3 % 50uring PHASE 4 Flavo 50% + 15% + 14% + 20% = 99% & Appearance Flavouring & Binding & Plant Sunflower of the 1% PHASE 1 Appearance Texturizing Proteins & Coconut cost Oils Water 20% 15% PHASE Sunflower Binding 2 Current industry challenge
Slide 33: POORK+ BEEF+
Enhanced plant-based ingredients with real animal proteins inside1. POORK+ BEEF+ SOY+PORK PEA+BEEF CRUELTY-FREE CRUELTY-FREE Safflower Soy Pea Dairy Ingredient Nutritional Oil Meat Replacement Meat Replacement Plant-based chymosin, a Plant-based GLA oil Plant-based real porcine Plant-based real bovi
Slide 34: Today most consumers accept GMO Food
Today most consumers accept GMO Food 98% of all soybeans grown in the USA are GMO, and Impossible Burger's successful rollout confirmed that GMO is no longer a material issue in the US consumer's minds1,2. Transparency and the cause's purpose are key Discussion gravitates around science, hunger and c
Slide 35: Regulatory Pathway
Regulatory Pathway Moolec is subject to the laws and regulations governing biotechnology and food companies in the jurisdictions in which we operate. Regulation of Plant Regulation of Food Other Regulatory Biotechnology Products and Ingredient Products Requirements Subject regulations and requiremen
Slide 36: Patent Portfolio
Patent Portfolio Moolec stands on a strong and growing IP strategy with great understanding of the biotech landscape offering a competitive advantage on its execution. 17 Patents A Australia United States Mexico Japan D P TENTE TE N Canada Brasil Argentina New Zealand D GLA E PAT NTED PATE Italy Ger
Slide 37: Latest Milestones
Latest Milestones Soybean Pea Chymosin SPC T1 seed harvested. Next phase for achieving Ongoing transformation Planted in Córdoba, T2 & T3 seeds started August 2022 and regeneration stage Argentina June 2022 Sample of seed protein extract expressing protein of interest GLA SPC x GLA Fermentation plat
Slide 38: Environmental, social and governance (ESG)
Environmental, social and governance (ESG)
Slide 39: Moolec addresses directly 10 of the 17 SDGs
Moolec addresses directly 10 of the 17 SDGs We use SDGs and 2030 Agenda as guidelines to strategically align our business in the search of the building of a more equitable, resilent and sustainable food system1,2. From ending poverty, hunger to responding to climate change, food and agriculture lie
Slide 40: Environmental & Social Impact
Enviromental & Social Impact 1 Moolec’s technology is much more friendly to the environment and promotes an inclusive global value chain, bringing farmers back to the equation. Main Concept Fermentation Cultured meat Molecular Farming Water usage Medium High Medium Low Energy eficiency Low Low High G
Slide 41: Focused on using all parts of the plants
Focused on using all parts of the plants 1 We create sustainable products and by-products following circular supplies and resource recovery strategies2. Plant & animal protein for main product 01 Leaves for carbon sequestration 05 and soil composting 02 Oils as high-valued by-product Fiber as source
Slide 42: Appendix
= 2 ‘ a Nw ae , : i; > > f & SR ie ry = Aon. *y cae am)
Slide 43: Transaction Overview – Capitalization, Sources, and Uses
Transaction Overview – Capitalization, Sources, and Uses Transaction Sources and Uses Redemptions Scenarios Pro–Forma Valuation Redemptions Scenarios Sources 0% 50% 100% 0% 50% 100% 1, 3 SPAC cash in trust1 $27.7 M $13.8 M $0.0 M Pro-Forma Shares Outstanding MM shares 39.3 37.9 37.69 Moolec shares (
Slide 44: Latest Detail Pro-Forma Ownership
Latest Detail Pro-Forma Ownership Number of Shares 0%1 50%1 100%1, 2 BG Farming Technologies Limited 14,570,000 37.0% 14,570,000 38.4% 14,570,000 38.8% Union Group Ventures Ltd. 14,570,000 37.0% 14,570,000 38.4% 14,820,0005, 8 39.5% Bioceres Crop Solutions Corp. 1,860,000 4.7% 1,860,000 4.9% 1,860,0
Slide 45: Let's empower science in food for the good of the planet
w Let’s empower e science in food for the good of a the planet r fo cker e o dha s . Follow us! www.moolecscience.com